Herpes simplex and herpes zoster eye disease: Presentation and management at a city hospital for the underserved in the United States

Eye and Contact Lens

Volumn 39, Issue 4, 2013, Pages 311-314

  Edell, Aimée R P ^a   Cohen, Elisabeth J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Health care utilization; Herpes simplex; Herpes zoster ophthalmicus; Herpes zoster vaccine; Zostavax

Indexed keywords

ACICLOVIR; FAMCICLOVIR; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL KERATITIS; CLINICAL FEATURE; CONSULTATION; CORNEA EDEMA; CORNEA STROMA; DISEASE ASSOCIATION; EMERGENCY PATIENT; FEMALE; GROUPS BY AGE; HERPES SIMPLEX; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICALLY UNDERSERVED; PRIORITY JOURNAL; UNITED STATES;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GUIDELINE ADHERENCE; HERPES ZOSTER OPHTHALMICUS; HERPESVIRUS VACCINES; HOSPITALS, URBAN; HUMANS; INCIDENCE; INFANT; KERATITIS, HERPETIC; MALE; MEDICALLY UNDERSERVED AREA; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; VULNERABLE POPULATIONS; YOUNG ADULT;

EID: 84880049029     PISSN: 15422321     EISSN: 1542233X     Source Type: Journal    
DOI: 10.1097/ICL.0b013e31829a3b47     Document Type: Article

References (22)

1. Leung J, Harpaz R, Molinari NA, et al. Herpes zoster incidence among insured people in the United States, 1993-2006: Evaluation of impact of varicella vaccination. Clin Infect Dis 2011;52: 332-340.
2. Chao DY, Chien YZ, Yeh YP, et al. The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000-2008. Epidemiol Infect 2012;140: 1131-1140.
3. Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005;20: 748-753. (Pubitemid 41141008)
4. Ragozzino MW, Melton LJ III, Kurland LT, et al. Population based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982;61: 310-316. (Pubitemid 12031812)
5. Liesegang TJ. Herpes zoster ophthalmicus: Natural history, risk factors, clinical presentation, and morbidity. Ophthalmology 2008;115:S3-S12. (Pubitemid 351173970)
6. Zhou F, Harpaz R, Jumaan AO, et al. Impact of varicella vaccination on health care utilization. JAMA 2005;294: 797-802. (Pubitemid 41175722)
7. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352: 2271-2284.
8. Ghaznawi N, Virdi A, Dayan A, et al. Herpes zoster ophthalmicus: Comparison of disease in patients 60 years and older versus younger than 60 years. Ophthalmology 2011;118: 2242-2250.
9. Goldman GS. Cost-benefit analysis of universal varicella vaccination in the US taking into account the related herpes-zoster epidemiology. Vaccine 2005;23: 3349-3355. (Pubitemid 40523130)
10. Centers for Disease Control and Prevention (CDC). Adult vaccination coverage-United States 2010. MMWR Morb Mortal Wkly Rep 2012; 61: 66-72.
11. The Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med 1998;339: 300-306.
12. Guess SM, Butt AL, Neely SB, et al. Disseminated knowledge from clinical trials for herpes simplex virus keratitis. Arch Ophthalmol 2010; 128: 1624-1625.
13. Centers for Disease Control and Prevention (CDC). Update on herpes zoster vaccine: Licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep 2011;66:1528.
14. Zostavax (zoster vaccine, live) [May 25, 2006 Approval Letter-Zostavax]. Whitehouse Station, NJ: Merck & Co. Inc.; 2006. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm132873. htm. Accessed July 29, 2012.
15. Zostavax (zoster vaccine, live) [March 24, 2011 Approval Letter-Zostavax]. Whitehouse Station, NJ: Merck Sharp and Dohme Corp.; 2006. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/ ucm248608.htm. Accessed July 29, 2012.
16. Schmader KE, Levin MJ, Gnann JW, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54: 922-928.
17. Notice to readers: Update on supply of vaccines containing varicella-zoster virus. JAMA 2007;298:736.
18. Burke BL, Steele RW, Beard OW. Immune responses to varicella-zoster in the aged. Arch Intern Med 1982;142: 291-293. (Pubitemid 12180803)
19. Gupta N, Sachdev R, Sinha R. Herpes zoster ophthalmicus: Disease spectrum in young adults. Middle East Afr J Ophthalmol 2011;18: 178-182.
20. Puri LR, Shrestha GB, Shah DN, et al. Ocular manifestations in herpes zoster ophthalmicus. Nepal J Ophthalmol 2011;3: 165-171.
21. Wilhelmus KR, Gee L, Hauck WW. Herpetic Eye Disease Study: A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology 1994;101: 1883-1896.
22. Severson EA, Baratz KH, Hodge DO. Herpes zoster ophthalmicus in Olmstead County, Minnesota. Arch Ophthalmol 2003;121: 386-390.